Elan Pharmaceuticals, Inc.

Elan Pharma International Limited

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Prothena Biosciences Limited

The Trustees of Flinders University

The Flinders University of South Australia

Jason Marc Goldstein

Tamie Chilcote

John P Anderson

Guriqbal Basi

Donald Walker

David Chereau

Normand L Frigon, Jr

Kelly Banducci

Tamie J Chilcote

Conrad Padraig Quinn

John Logan Anderson

Irene Griswold-Prenner

Dennis A Bagarozzi, Jr

Irene Griswold

Tami J Chilcote

Wei Ping Gai

Wei Ping c/o Department Of Human Physiology Gai

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

Antibodies to alpha synuclein

Provided are antibodies capable of binding to a particular epitope or specifically binding to LF or LTx and enhancing the activity of the LF or LTx relative to the LF or LTx absent the antibody binding.

Regulating Bacillus anthracis lethal factor activity via an activating epitope region

The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.

Alpha-synuclein kinase

The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.

Truncated fragments of alpha-synuclein in Lewy body disease

The application identifies fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

Growing community of inventors

Decatur, GA, United States of America

Jason Marc Goldstein